Monitoring von Tienopyridinen und GPIIb/IIIa-Antagonisten

Zusammenfassung

Thrombozytenfunktionstests galten in der Vergangenheit als mystifizierte, komplizierte und zeitaufwändige Untersuchungen mit hohem Variationskoeffizient bezüglich Präzision. Sie ermöglichten zudem oft keine schlüssige Interpretation unter Routinebedingungen im klinischen Labor. Diese Tests wurden primär zur Evaluierung von Störungen der primären Hämostase eingesetzt. Nur wenige erfassten auch die Plättchenhyperreaktivität. Diese Zusammenfassung der Präsentation im Rahmen des GTH-Symposiums 2004 gibt einen Überblick über eine Auswahl von einfachen, leicht handhabbaren Plättchenfunktionstests, die sich zum Monitoring der Therapie mit Tienopyridinen und Glykoprotein-IIb/IIIa-Rezeptor-Antagonisten eignen könnten.

Summary

Platelet function analyses were known as mystified, complicated, and time consuming laboratory investigations with a high coefficient of variation. Only in rare cases they led to precise interpretations under routine clinical laboratory conditions. In the first line they were focussed on bleeding tendencies. Only few were suited to evaluate the state of hyperaggregability of platelets. This short presentation of the GTH-Symposium 2004 gives a survey on the most simple and practicable tests for checking platelet function which may be used for the monitoring of therapy with tienopyridines and glycoprotein IIb/IIIa-receptor antagonists.

Schlüsselwörter

Plättchenfunktionstest - Monitoring - Tienopyridine - Glykoprotein-IIb/IIIa-Rezeptor-Antagonisten

Keywords

Platelet function tests - monitoring - tienopyridine - gpIIb/IIIa-antagonists

• Literatur

• 1 Coller BS, Lang D, Scudder LE. Rapid and simple platelet function assay to assess glycoprotein IIb/IIIa blockade. Circulation 1997; 4: 860-7.
• 2 Graff J, Harder S. Investigation of PADA as a method to monitor GPIIb/IIIa-inhibitors and other antiplatelet agents. Semin Thromb Haemost. 2004 (in press).
• 3 Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb Res 1993; 71: 397-403.
• 4 Grotemeyer KH. The platelet-reactivity-test: a useful by-product of the blood-sampling procedure?. Thromb Res 1991; 61: 423-31.
• 5 Hezard N, Metz D, Nazeyrollas P. et al. Use of the PFA-100 Apparatus to assess platelet function in patients undergoing PTCA during and after infusion of cE3 Fab in the presence of other antiplatelet agents. Thromb Haemost 2000; 83: 540-4.
• 6 Krischek B, Klinkhardt U, Wieding JU. et al. Specificity of Retentiontest Homburg (RTH) in evaluating platelet hyperactivity and in monitoring the therapy with antiplatelet drugs. Semin Thromb Haemost. 2004 (in press).
• 7 Lange RA, Hillis LD. Antiplatelet therapy for ischemic heart disease. N Engl J Med 2004; 350: 277-80.
• 8 Mueller T, Haltmayer M, Poelz W. et al. Monitoring Aspirin 100 mg and Clopidogrel 75 mg therapy with the PFA-100 device in patients with peripheral arterial disease. Vasc Endovasc Surgery 2003; 37: 117-23.
• 9 Nowak G, Wiesenburg A, Schumann A. et al. Platelet adhesion assay (PADA) – a new quantitative whole blood test to measure current platelet function. Semin Thromb Haemost. 2004 (in press).
• 10 Osende JI, Fuster V, Lev EI. et al. Testing platelet activation with a shear-dependent platelet function test versus aggregation-based tests: relevance for monitoring long-term glycoprotein IIb/IIIa inhibition. Circulation 2001; 103: 1488-91.
• 11 Shenkman B, Savion N, Dardik R. et al. Testing of platelet deposition on polystyrene surface under flow conditions by the cone and plate(let) analyser: role of platelet activation, fibrinogen and von Willebrand factor. Thromb Res 2000; 99: 353-61.
• 12 Steinhubl SR, Tally JD, Braden GA. et al. Pointof-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation 2001; 103: 2572-8.
• 13 Van der Planken MG, Claeys MJ, Vertessen FJ. et al. Comparison of turbidimetric aggregation and in vitro beeding time (PFA-100) for monitoring the platelet inhibitory profile of antiplatelet agents in patients undergoing stent implantation. Thromb Res 2003; 111: 159-64.
• 14 Varon D, Dardik R, Shenkman B. et al. A new method for quantitative analysis of whole blood platelet interaction with extracellular matrix under flow conditions. Thromb Res 1997; 85: 283-94.
• 15 Wheeler GL, Braden GA, Steinhubl SR. et al. The Ultegra rapid platelet-function assay: comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapy. Am Heart J. 2002; 143: 602-11.
• 16 Wu KK, Hoak JC. A new method for the quantitative detection of platelet aggregates in patients with arterial insufficiency. Lancet 1974; 2 (7886): 924-6.
• 17 Ziegler S, Maca T, Alt E. et al. Monitoring of antiplatelet therapy with the PFA-100 in peripheral angioplasty patients. Platelets 2002; 13: 493-7.